Coherus Oncology, Inc. — Form 8-K
Filed August 17, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 67/100
What the filing says
Coherus Oncology, Inc. and three subsidiaries (Coherus Intermediate Corp, Surface Oncology LLC, Intekrin Therapeutics Inc.) entered into a Loan and Security Agreement dated August 12, 2026 with Innovatus Life Sciences Lending Fund I, LP as collateral agent. The agreement provides a $55M Term A Loan (funded immediately), $25M Term B Loan (conditional on achieving $35M trailing three-month revenue by March 31, 2028), and up to $20M Term C Loan (at lender discretion). Interest accrues at Prime Rate + 6.75% (floor 6.75%) + 4.15%; amortization begins September 1, 2029 (or 2030 if Term B milestone met). Repayment is due August 14, 2031. All company assets are pledged as collateral; prepayment triggers 3-5% fees declining to zero after three years.
Why this rating
$55M immediate credit is 67% of company's $81.9M market cap—meaningful but not transformational. Financing extends runway; however, high fees, asset pledge, and strict covenants impose material constraints on operations and future flexibility.
See more from August 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.